Verma S, David JP, Leiter LA, Michelsen MM, et al. Semaglutide reduces risk of MACE consistently across baseline triglyceride levels in patients with type 2 diabetes: Post Hoc Analyses of SUSTAIN 6 and PIONEER 6 trials. Diabetes Obes Metab 2023 Apr 4. doi: 10.1111/dom.15081.
PMID: 37016488